Clinical Trial

Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison

Study acronym: GDW
Recruiting
View on ClinicalTrials.gov →
Summary
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-26; most recent amendment 2026-01-29.
Status change: Enrolling by Invitation → Recruiting 2025-12-10
Trial Details
NCT Number NCT07272616
Lead Sponsor Region Stockholm
Conditions Brain Neoplasms
Enrollment 100 participants
Start Date 2026-01-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30